Loading clinical trials...
Loading clinical trials...
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial
Conditions
Interventions
Cytarabine
Venetoclax
+2 more
Start Date
October 23, 2024
Primary Completion Date
February 1, 2026
Completion Date
February 1, 2027
Last Updated
July 3, 2024
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06326268
Lead Sponsor
Eastern Cooperative Oncology Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions